Page last updated: 2024-08-26

nicotine and gsk 1034702

nicotine has been researched along with gsk 1034702 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bentley, GD; Bullmore, ET; Croft, RJ; Davies, CH; Dodds, CM; Jones, GA; Laruelle, M; Lawrence, P; Lund, J; Maruff, P; Nathan, PJ; O'Neill, BV; Peters, G; Robertson, J; Swirski, B; Watson, J; Watson, S	1

Trials

1 trial(s) available for nicotine and gsk 1034702

Article	Year
The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. The international journal of neuropsychopharmacology, 2013, Volume: 16, Issue:4 Topics: Adult; Allosteric Regulation; Behavior, Addictive; Benzimidazoles; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Humans; Male; Memory, Episodic; Middle Aged; Nicotine; Receptor, Muscarinic M1; Smoking; Smoking Cessation; Young Adult	2013

Article

Year

The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction.

The international journal of neuropsychopharmacology, 2013, Volume: 16, Issue:4

Topics: Adult; Allosteric Regulation; Behavior, Addictive; Benzimidazoles; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Humans; Male; Memory, Episodic; Middle Aged; Nicotine; Receptor, Muscarinic M1; Smoking; Smoking Cessation; Young Adult

2013